Literature DB >> 23735316

Barriers to drug delivery in interventional oncology.

Rahul A Sheth1, Robin Hesketh, David S Kong, Stephan Wicky, Rahmi Oklu.   

Abstract

Although much attention has been paid to mechanisms of anticancer drug resistance that focus on intracellular processes that protect tumor cells, it has recently become increasingly evident that the unique features of the tumor microenvironment profoundly impact the efficacy of cancer therapies. The properties of this extracellular milieu, including increased interstitial pressure, decreased pH, hypoxia, and abnormal vascularity, result in limited drug efficacy; this finding is true not only for systemic chemotherapy but also for catheter-based therapies, including chemoembolization and radioembolization. The present review summarizes the barriers to drug delivery imposed by the tumor microenvironment and provides methods to overcome these hurdles.
Copyright © 2013 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DEB; ECM; HIF; IFP; RF; VEGF; drug-eluting bead; extracellular matrix; hypoxia-inducible factor; interstitial fluid pressure; radiofrequency; vascular endothelial growth factor

Mesh:

Substances:

Year:  2013        PMID: 23735316     DOI: 10.1016/j.jvir.2013.03.034

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  14 in total

Review 1.  Advances in Biomaterials and Technologies for Vascular Embolization.

Authors:  Jingjie Hu; Hassan Albadawi; Brian W Chong; Amy R Deipolyi; Rahul A Sheth; Ali Khademhosseini; Rahmi Oklu
Journal:  Adv Mater       Date:  2019-06-06       Impact factor: 30.849

Review 2.  Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care?

Authors:  Richard L Hesketh; Andrew X Zhu; Rahmi Oklu
Journal:  Am J Clin Oncol       Date:  2015-08       Impact factor: 2.339

Review 3.  Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma?

Authors:  Richard L Hesketh; Andrew X Zhu; Rahmi Oklu
Journal:  Diagn Interv Radiol       Date:  2015 Jan-Feb       Impact factor: 2.630

Review 4.  Thrombosis in cancer patients: etiology, incidence, and management.

Authors:  Rahul A Sheth; Andrew Niekamp; Keith B Quencer; Fadi Shamoun; Martha-Gracia Knuttinen; Sailendra Naidu; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

5.  High lung shunt fraction in colorectal liver tumors is associated with distant metastasis and decreased survival.

Authors:  Amy R Deipolyi; A John Iafrate; Andrew X Zhu; Emel A Ergul; Suvranu Ganguli; Rahmi Oklu
Journal:  J Vasc Interv Radiol       Date:  2014-07-30       Impact factor: 3.464

6.  Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood.

Authors:  Jiahe Li; Charles C Sharkey; Dantong Huang; Michael R King
Journal:  Cell Mol Bioeng       Date:  2015-02-24       Impact factor: 2.321

Review 7.  Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine.

Authors:  Dongxi Xiang; Sarah Shigdar; Greg Qiao; Tao Wang; Abbas Z Kouzani; Shu-Feng Zhou; Lingxue Kong; Yong Li; Chunwen Pu; Wei Duan
Journal:  Theranostics       Date:  2015-01-01       Impact factor: 11.556

8.  Neutrophil extracellular traps are increased in cancer patients but does not associate with venous thrombosis.

Authors:  Rahmi Oklu; Rahul A Sheth; Keith H K Wong; Amin H Jahromi; Hassan Albadawi
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

9.  Doxorubicin-loaded hollow gold nanospheres for dual photothermal ablation and chemoembolization therapy.

Authors:  Rahul A Sheth; Xiaoxia Wen; Junjie Li; Marites P Melancon; Xin Ji; Y Andrew Wang; Cheng-Hui Hsiao; Diana S-L Chow; Elizabeth M Whitley; Chun Li; Sanjay Gupta
Journal:  Cancer Nanotechnol       Date:  2020-07-01

10.  Mechanism of action and efficacy of LY2109761, a TGF-β receptor inhibitor, targeting tumor microenvironment in liver cancer after TACE.

Authors:  Xiaojun He; Xiaopeng Guo; Hongsen Zhang; Xiangchuang Kong; Fan Yang; Chuansheng Zheng
Journal:  Oncotarget       Date:  2017-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.